BioIQ Supports American Heart Month To Raise Awareness About Heart Disease, The #1 Killer Of Women

BioIQ Supports American Heart Month To Raise Awareness About Heart Disease, The #1 Killer Of Women
Yes, the truth sometimes hurts. But when it comes to women's health, it's better to face the facts: one in four women in the United States dies of heart disease. Although significant progress has been made in increasing awareness among women, most people fail to make the connection between risk factors and their personal risk for developing heart disease.

Pharmaceuticals Sold In Sweden Cause Serious Environmental Harm In India

Pharmaceuticals Sold In Sweden Cause Serious Environmental Harm In India
Many of the substances in our most common medicines are manufactured in India and China. Some of these factories release large quantities of antibiotics and other pharmaceutical substances to the environment. There is an obvious risk of these releases leading to resistant bacteria.

CyDex Pharmaceuticals Announces Successful Completion Of Phase II Clinical Trial For Budesonide/Azelastine Combination Solution Nasal Spray

CyDex Pharmaceuticals Announces Successful Completion Of Phase II Clinical Trial For Budesonide/Azelastine Combination Solution Nasal Spray
CyDex Pharmaceuticals, Inc. announced that it has successfully completed an early proof-of-concept phase II clinical trial of its Captisol-Enabled® budesonide/azelastine nasal spray for seasonal allergic rhinitis (SAR). CyDex has an international PCT patent application pending for this combination nasal spray product.